Table 3 Demographic and clinical characteristics of patients according to ICU survival status.

From: Presence of cholestasis and its impact on survival in SARS-CoV-2 associated acute respiratory distress syndrome

Variable

All patients

Survivors

Non-survivors

P

N (%)

225

141 (63)

84 (37)

 

Male, n (%)

154 (68)

96 (68)

58 (69)

0.998

Age (years), mean (SD)

56.2 (12.1)

53.0 (12.3)

61.7 (9.8)

< 0.001

BMI, kg/m2 mean (SD)

32 (7.5)

32.1 (7.3)

32.0 (7.9)

0.951

Comorbidities

    

Diabetes, n (%)

67 (30)

37 (26)

30 (36)

0.176

Obesity, n (%)

100 (44)

59 (42)

41 (49)

0.38

Arterial hypertension, n (%)

128 (57)

71 (50)

57 (68)

0.015

Chron. lung disease, n (%)

30 (13)

14 (10)

16 (19)

0.081

Chron. liver disease, n (%)

18 (8)

7 (5)

11 (13)

0.055

Chron. kidney disease, n (%)

18 (8)

7 (5)

11 (13)

0.055

SOFA, median (IQR)

8 (7–10)

7 (7–9)

9 (7–11)

< 0.001

SAPSII, median (IQR)

41 (34–51)

38 (32–46)

46 (39–53)

< 0.001

APACHEII, median (IQR)

19 (14–22)

17 (13–21)

21 (16–25)

0.001

P/F ratio nadir, median (IQR)

60 (52–71)

64 (57–76)

52 (47–61)

< 0.001

ICU LOS (days), median (IQR)

30 (15–50)

32 (16–56)

28 (14–41)

0.081

IMV, n (%)

210 (93)

126 (89)

84 (100)

0.005

IMV (days), median (IQR)

28 (12–45)

28 (12–48)

26 (11–39)

0.345

Prone position, n (%)

177 (79)

107 (76)

70 (83)

0.25

Prone position (days), median (IQR)

4 (1–8)

4 (1–8)

5 (2–9)

0.047

ECMO, n (%)

130 (58)

76 (54)

54 (64)

0.166

ECMO (days), median (IQR)

23 (13–35)

14 (0–32)

22 (9–32)

< 0.001

Norepinephrine, n (%)

209 (93)

125 (89)

84 (100)

0.003

Norepinephrine (days), median (IQR)

12 (6–26)

10 (4–23)

15 (9–29)

0.005

Vasopressin, n (%)

38 (17)

12 (9)

26 (31)

< 0.001

Dobutamine, n (%)

34 (15)

17 (12)

17 (20)

0.143

Ketamine, n (%)

184 (82%)

110 (78)

74 (88)

0.086

Ketamine (days), median (IQR)

10 (3–17)

9 (3–15)

12 (5–20)

0.052

Neuromuscular blockade, n (%)

144 (64)

85 (60)

59 (70)

0.174

Neuromuscular blockade (days), median (IQR)

2 (0–5)

2 (0–5)

3 (0–6)

0.041

Parenteral nutrition, n (%)

149 (66)

88 (62)

61 (73)

0.156

Parenteral nutrition (days), median (IQR)

5 (0–11)

4 (0–9)

7 (0–14)

0.015

Cholestasis, n (%)

119 (53)

66 (47)

53 (63)

0.026

UDCA, n (%)

107 (48)

61 (43)

46 (55)

0.100

UDCA (mg/kg BW), median (IQR)

15 (10–18)

15 (10–18)

14 (9–17)

0.323

  1. n., number of patients; %, percent; IQR, interquartile range; SD, standard deviation; Surv., survivors; SOFA, Sequential Organ Failure Assessment Score; SAPSII, Simplified Acute Physiology Score II; APACHEII, Acute Physiology and Chronic Health Evaluation II Score; P/F ratio, PaO2/FiO2; ICU, intensive care unit; LOS, length of stay; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; UDCA, ursodeoxycholic acid; BW, body weight.
Back to article page